Allianz Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Allianz Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-13,700	Closed	-$103K	–	2016
2025 Q1	$103K	Buy	13,700 +1,200	+10%	+$9.68K	﹤0.01%	2169
2024 Q4	$94K	Buy	+12,500	New	+$94.9K	﹤0.01%	2147
2023 Q4	–	Sell	-33,300	Closed	-$236K	–	2137
2023 Q3	$236K	Hold	33,300	–	–	﹤0.01%	2111
2023 Q2	$234K	Buy	33,300 +10,900	+49%	+$87.5K	﹤0.01%	1874
2023 Q1	$187K	Sell	22,400 -23,900	-52%	-$230K	﹤0.01%	2047
2022 Q4	$532K	Sell	46,300 -13,400	-22%	-$167K	﹤0.01%	1715
2022 Q3	$752K	Sell	59,700 -385,975	-87%	-$4.97M	﹤0.01%	1464
2022 Q2	$4.71M	Buy	445,675 +140,496	+46%	+$1.45M	﹤0.01%	1124
2022 Q1	$4.96M	Buy	305,179 +42,064	+16%	+$675K	﹤0.01%	1233
2021 Q4	$3.64M	Buy	263,115 +119,407	+83%	+$1.58M	﹤0.01%	1354
2021 Q3	$2.06M	Buy	+143,708	New	+$2.27M	﹤0.01%	1648
2020 Q3	–	Sell	-13,637	Closed	-$65K	–	1907
2020 Q2	$65K	Buy	+13,637	New	+$54.5K	﹤0.01%	2354
2019 Q4	–	Sell	-107,890	Closed	-$309K	–	2766
2019 Q3	$309K	Sell	107,890 -157,254	-59%	-$489K	﹤0.01%	2519
2019 Q2	$1M	Sell	265,144 -69,584	-21%	-$419K	﹤0.01%	2133
2019 Q1	$2.73M	Buy	334,728 +65,325	+24%	+$559K	﹤0.01%	1725
2018 Q4	$2.17M	Sell	269,403 -9,015	-3%	-$70.1K	﹤0.01%	1742
2018 Q3	$2.12M	Buy	278,418 +48,005	+21%	+$322K	﹤0.01%	1913
2018 Q2	$1.32M	Sell	230,413 -1,348	-0.6%	-$7.42K	﹤0.01%	2118
2018 Q1	$1.1M	Buy	231,761 +66,783	+40%	+$343K	﹤0.01%	2176
2017 Q4	$810K	Buy	164,978 +5,614	+4%	+$27.2K	﹤0.01%	2296
2017 Q3	$835K	Buy	159,364 +41,727	+35%	+$214K	﹤0.01%	2305
2017 Q2	$654K	Sell	117,637 -2,341	-2%	-$14.3K	﹤0.01%	2355
2017 Q1	$1.01M	Buy	+119,978	New	+$835K	﹤0.01%	2237
2015 Q4	–	Sell	-21,670	Closed	-$247K	–	2446
2015 Q3	$247K	Buy	+21,670	New	+$289K	﹤0.01%	2235

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Allianz Asset Management's BCRX Position: Q2 2025 in Review

Allianz Asset Management sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2025, closing a stake of 13,700 shares — an estimated $103K sold.

Allianz Asset Management first reported a position in BCRX in Q3 2015 and held it in 24 quarters. The position peaked at $4.96M in Q1 2022. 294 funds tracked by Wall St. Rank hold BCRX as of Q2 2025.

Allianz Asset Management reported no remaining BioCryst Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Allianz Asset Management sold 13,700 BioCryst Pharmaceuticals shares in Q2 2025, an estimated $103K.
Allianz Asset Management first reported a position in BioCryst Pharmaceuticals in Q3 2015 and held it in 24 quarters.
Allianz Asset Management's BioCryst Pharmaceuticals position peaked at $4.96M in Q1 2022.
294 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2025.

Based on Allianz Asset Management's 13F filing for Q2 2025, filed 28 Jul 2025.